^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    ArcherMET

    Company:
    Invitae Corp
    Type:
    Other Approval
    Related tests:
    17d
    Emergency department Nurses' narratives of burnout: Changing roles and boundaries. (PubMed, Int Emerg Nurs)
    The conclusions of this study are transferable to a variety of acute health services. Health service management have a role to promote a positive workplace culture for nurses, which advocates for home life balance. This will support nurses to construct clear boundaries between professional identity and their personal lives.
    Journal
    |
    ArcherMET
    4ms
    Process and experience of youth researchers within a Health Promoting Schools study in Nova Scotia, Canada. (PubMed, Health Promot Int)
    The research also highlights the benefits of engaging youth in YPAR. Future research will report on the findings from the peer interviews.
    Journal
    |
    ArcherMET
    9ms
    Liquid biopsies (LBx) and tissue biopsies (TBx) for identifying MET exon 14 (METex14) skipping in advanced NSCLC: Analyses from the phase II VISION study of tepotinib (ESMO 2023)
    Differences in populations identified by TBx and LBx should be considered when interpreting trial data. Table: 1382P
    P2 data • Liquid biopsy • Metastases • Biopsy
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET exon 14 mutation
    |
    Guardant360® CDx • ArcherMET • Oncomine Focus Assay
    |
    Tepmetko (tepotinib)
    over1year
    Success of Tepotinib Therapy in Overcoming Resistance to Osimertinib in a Patient with EGFR-Mutant Lung Adenocarcinoma With a Potential Acquired MET Exon 14 Skipping Mutation (IASLC-ACLC 2022)
    "We described a patient with lung adenocarcinoma harboring METex14del as a potential acquired resistance to osimertinib, who responded to subsequent tepotinib therapy. Re-biopsy and re-analysis of genetic profiles should be considered in NSCLC patients who develop osimertinib resistance."
    Clinical
    |
    EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    EGFR mutation • EGFR L858R • EGFR T790M • MET exon 14 mutation • MET mutation • EGFR positive
    |
    cobas® EGFR Mutation Test v2 • Oncomine™ Comprehensive Assay v3M • ArcherMET • AmoyDx® Essential NGS Panel
    |
    Tagrisso (osimertinib) • Tepmetko (tepotinib)
    almost2years
    Discrepancy in MET Exon 14 Skipping Mutation Measurement Between ArcherMET and Oncomine Dx Target Test System (IASLC-WCLC 2022)
    One of the selective oral MET inhibitors, tepotinib, is only used in Japan when METex14skipping is detected by ArcherMET, a next generation sequencer... The discrepancies observed between these systems may be owing to low allele frequencies. More analysis for these are warranted.
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET exon 14 mutation • MET exon 14 deletion
    |
    Oncomine™ Dx Target Test • ArcherMET
    |
    Tepmetko (tepotinib)
    over2years
    An alert to possible false positives with a commercial assay for METex14 skipping. (PubMed, J Thorac Oncol)
    "While the caution in detecting METex14 skipping focuses on false negatives in the literature, false positives were first noted at a relatively high frequency (8 of 26, 30.8%) in this study. According to the results of previous clinical trials using the other tyrosine kinase inhibitors, it could be surmised that MET inhibitor treatment in patients without METex14 skipping is detrimental. Clinicians need to be alert to the false-positives that can lead to harmful treatments."
    Journal
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET exon 14 mutation
    |
    ArcherMET
    |
    Tepmetko (tepotinib) • Tabrecta (capmatinib)